Optimize Your Health - Available Everywhere in the US

  188-8981-6784    HIPAA Compliant  ยท  Licensed U.S. Providers

Tesamorelin

Tesamorelin โ€” FDA-Approved GHRH Analogue for Lipodystrophy. Physician-Supervised

Tesamorelin is an FDA-approved, stabilised GHRH analogue with a well-established clinical track record. It holds approval for HIV-related lipodystrophy โ€” a condition involving abnormal visceral fat accumulation โ€” and is being investigated in other metabolic contexts including age-related visceral adiposity. It is available at OptiMale USA following thorough clinical assessment.

WHAT IS IT?

Understanding Tesamorelin

esamorelin is a modified form of GHRH that includes a trans-3-hexenoic acid group attached to the N-terminus, which stabilises the molecule against enzymatic degradation and extends its activity compared to native GHRH. It activates GHRH receptors in the pituitary, stimulating GH release in a physiological, pulsatile pattern โ€” the same mechanism used by sermorelin and CJC-1295, but with FDA-approved clinical backing for a specific indication.
Its FDA approval for HIV-related lipodystrophy โ€” where antiretroviral therapy causes characteristic visceral fat accumulation โ€” is based on strong randomised clinical trial data showing significant reduction in trunk fat. This clinical evidence base distinguishes tesamorelin from most other GH peptides, which do not have equivalent approved indications. Research is also examining tesamorelin’s potential in age-related visceral adiposity and metabolic health beyond the HIV context. At OptiMale USA, tesamorelin is discussed in the context of your full metabolic and body composition assessment.

tesamorelin
Quick Facts

Injection

Timeline: Measurable visceral fat reduction at 8-12 weeks; optimal results at 26 weeks
Lab required: Yes
Ongoing maintenance: Yes; continued therapy recommended for sustained visceral fat reduction
Pricing:ย  Contact for Pricing

Related Treatments

Benefits

FDA-approved with randomised clinical trial evidence

Tesamorelin's approval for lipodystrophy is backed by multiple randomised controlled trials showing significant trunk fat reduction. This clinical evidence base is stronger than most peptides in the GH category and informs how providers discuss its use in appropriate metabolic contexts.

Visceral fat research

Research has specifically examined tesamorelin's effects on visceral fat โ€” the metabolically active fat that accumulates around abdominal organs. This distinct focus on trunk fat reduction, documented in clinical trials, is what differentiates tesamorelin's research profile from general GH secretagogues.

Physiological GH release maintained

Like other GHRH analogues, tesamorelin stimulates pituitary GH release in a pulsatile pattern rather than producing constant GH elevation. This physiological approach maintains the body's natural feedback mechanisms.

Body composition research beyond lipodystrophy

Researchers have investigated tesamorelin's effects on body composition markers in populations beyond its approved indication, including men with age-related visceral fat accumulation and declining GH. These are areas of ongoing investigation.

Who Is This For?

Am I a Good Candidate?

Ideal For

  • Men with documented visceral fat accumulation and low or declining GH levels confirmed through bloodwork
  • Men with metabolic syndrome or elevated trunk fat who have been assessed at OptiMale USA
  • Men on antiretroviral therapy experiencing lipodystrophy changes in body fat distribution
  • Men whose provider has assessed them as appropriate for a GHRH analogue with specific visceral fat research focus

Not Recommended If

  • Men with active malignancy
  • Men with pituitary tumours or significantly elevated baseline IGF-1
  • Men with hypothyroidism not under active treatment โ€” GH increase can unmask thyroid deficiency
  • Men under 25 or with open growth plates
Safety

Potential Side Effects

Tesamorelin has a well-characterised safety profile from its clinical trial programme. Side effects are generally mild and similar to other GHRH analogues. IGF-1 monitoring is standard throughout all protocols.

Common Questions

Frequently Asked Questions

Get started

Discuss Tesamorelin With a Provider

Your free consultation is the first step. A licensed OptiMale USA provider will review your bloodwork, health history, and goals before making any recommendations.

These statements have not been evaluated by the Food and Drug Administration. The information on this website is provided for educational and informational purposes only and does not constitute medical advice, a diagnosis, a treatment recommendation, or an offer to prescribe, supply, compound, administer, or dispense any product.

Compounded medications. Compounded medications, including compounded semaglutide and compounded tirzepatide, are not FDA-approved and are not generic equivalents of brand-name products such as Ozempicยฎ, Wegovyยฎ, Mounjaroยฎ, or Zepboundยฎ. The FDA does not review compounded drugs for safety, effectiveness, or quality prior to dispensing. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities pursuant to a valid prescription from a licensed provider following individual patient evaluation. Availability of compounded medications varies by state and is subject to applicable state and federal law.

Research compounds. Certain compounds referenced on this website are research compounds that are not approved by the FDA for human use and have not been evaluated by the FDA for safety, efficacy, or quality. Information about these compounds is provided solely for educational and informational purposes and reflects publicly available scientific literature. OptiMale USA and its affiliated providers do not prescribe, supply, recommend, compound, administer, or dispense research compounds, and nothing on this website should be construed as an offer to do so. Patient consent forms purporting to waive provider duty of care with respect to research compounds are not recognized as a defense to professional liability and are not used by OptiMale USA.

Clinical services. All prescription products and services offered through OptiMale USA are prescribed exclusively by board-certified, licensed U.S. providers following individual clinical evaluation, comprehensive bloodwork where indicated, and a detailed health assessment. Available services and products vary by state based on provider licensure and applicable law. No provider-patient relationship is established by use of this website; a provider-patient relationship is formed only upon completion of a clinical evaluation with a licensed OptiMale USA provider.

Individual results vary. Always consult a qualified healthcare provider before beginning any new health protocol.

  • Home
  • Products
  • Solutions
  • How it Works
  • Peptide Library